Generics Drugmakers Prepare for Supply Chain, Exclusivity Fight

Jan. 25, 2021, 11:00 AM

The generic drug industry is gearing up for a busy year with lawmakers mulling changes to the pharmaceutical supply chain and how medicines are priced.

The Covid-19 pandemic sparked fears among U.S. regulators and lawmakers around drug shortages and U.S. reliance on foreign medicine producers, particularly for the ingredients crucial to generic drugs.

“A large part of the conversation, particularly in early 2020, was whether we are too reliant on one part of the world for manufacturing,” said Erik Komendant, vice president of federal affairs for the Association for Accessible Medicines, the main lobbying organization for Teva Pharmaceutical Industries Ltd....

To read the full article log in. To learn more about a subscription click here.